About Intrommune Therapeutics
Intrommune Therapeutics is a private company based in New York, New York, incorporated in 2021 in Delaware. It has reported $3,556,883 raised in four offerings on Form D since April 2018.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 6, 2023 | Jan 22, 2024 | $210,000of $10.0M target | 7 | $30,000 | Debt, Options, Note convertible into equity upon occurrence of certain eventsRule 506(b) | Form D ↗ |
| Mar 16, 2022 | Jan 22, 2024 | $3,278,840fully sold | 15 | $218K | Debt, Options, Note convertible into equity upon occurrence of certain eventsRule 506(b) | Form D ↗ |
| Jul 2, 2021 | Jun 23, 2021amended Jul 8, 2021 | $68,043of $20.0M target | 6 | $11,341 | EquityRule 506(c) | Form D/A ↗1 earlier filing |
| Apr 12, 2018 | Apr 12, 2018 | $0of $2.0M target | 0 | — | EquityRule 506(c) | Form D ↗ |
| Total, four offerings | $3,556,883 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Intrommune Therapeutics's Form D filed Jan 22, 2024.
JR
Jonathan Rich
Director
WR
William Reisacher
Director
MN
Michael Nelson
President and director
HP
Hemanshu Pandya
Director
EB
Erick Berglund
Director
Earlier filings also listed Anthony Robinson (promoter, last listed Apr 2018).